ALUR
Allurion Technologies Inc.NYSEHealthcare$0.88+3.53%ClosedMarket Cap: $6.6M
As of 2026-04-04
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.86
P/S
0.44
EV/EBITDA
-1.61
DCF Value
$-37.12
FCF Yield
-436.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
62.8%
Operating Margin
-198.0%
Net Margin
-188.8%
ROE
39.1%
ROA
-182.3%
ROIC
-558.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.6M | 44.5% | $-6.3M | $-6.0M | $-0.69 | — |
| FY 2025 | $15.2M | 62.8% | $-30.2M | $-28.8M | $-3.81 | — |
| Q3 2025 | $2.7M | 49.1% | $-9.6M | $-11.9M | $-1.53 | — |
| Q2 2025 | $3.4M | 73.9% | $-7.0M | $-9.3M | $-1.28 | — |
| Q1 2025 | $5.6M | 74.6% | $-7.3M | $-1.5M | $-0.31 | — |
| Q4 2024 | $5.6M | 45.3% | $-17.1M | $-20.6M | $-7.94 | — |
| FY 2024 | $32.1M | 67.0% | $-50.2M | $-26.1M | $-11.64 | — |
| Q3 2024 | $5.4M | 58.0% | $-12.3M | $-9.0M | $-3.51 | — |
| Q2 2024 | $11.8M | 76.4% | $-9.3M | $-8.3M | $-4.34 | — |
| Q1 2024 | $9.4M | 73.2% | $-11.4M | $5.6M | $1.01 | — |
| Q4 2023 | $8.2M | 78.1% | $-25.7M | $-19.2M | $-10.09 | — |
| FY 2023 | $53.5M | 77.6% | $-79.1M | $-80.6M | $-57.83 | — |